DR. FRANCIS J MCMAHON, MD
Psychiatric in Bethesda, MD
License number
Maryland D37624
Category
Psychiatric
Type
Psychiatry
Address
Address
35 Convent Dr ROOM 1A202, Bethesda, MD 20892
Phone
(301) 451-4453
Personal information
See more information about FRANCIS J MCMAHON at radaris.comName
Address
Phone
5705 Cromwell Dr, Bethesda, MD 20816
5505 Charlcote Rd, Bethesda, MD 20817
1127 Linden Ave, Halethorpe, MD 21227
17110 Longdraft Rd, Gaithersburg, MD 20878
Organization information
See more information about FRANCIS J MCMAHON at bizstanding.comFrancis J Mcmahon, MD
35 Convent Dr Room, Bethesda, MD
Industry:
Psychiatrist
Phone:
(301) 451-4453 (Phone)
Francis J McMahon MD
35 Convent Dr, Bethesda, MD 20892
Categories:
Physicians & Surgeons
Phone:
(301) 451-4453 (Phone)
Professional information
Dr. Francis J Mcmahon, Bethesda MD - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Psychiatry)
Address:
National Institute Of Health
35 Convent Dr, Bethesda 20892
(301) 451-4453 (Phone)
35 Convent Dr, Bethesda 20892
(301) 451-4453 (Phone)
Certifications:
Psychiatry, 1993
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
National Institute Of Health
35 Convent Dr, Bethesda 20892
Washington Adventist Hospital
7600 Carroll Ave, Takoma Park 20912
35 Convent Dr, Bethesda 20892
Washington Adventist Hospital
7600 Carroll Ave, Takoma Park 20912
Education:
Medical School
Johns Hopkins University / School of Medicine
Graduated: 1987
Francis Scott Key Med Ctr
The Johns Hopkins Hospital
Johns Hopkins University / School of Medicine
Graduated: 1987
Francis Scott Key Med Ctr
The Johns Hopkins Hospital
Chief, Human Genetics Branch At National Institute Of Mental Health
Position:
Chief, Human Genetics Branch at National Institute of Mental Health
Location:
Washington D.C. Metro Area
Industry:
Research
Work:
National Institute of Mental Health
- United States since Sep 2010
-
Chief, Human Genetics Branch
National Institutes of Health
- Bethesda, MD 2002 - 2010
-
Chief, Unit on Genetic Basis of Mood & Anxiety Disorders
University of Chicago
1998 - 2002
-
Associate Professor
Johns Hopkins School of Medicine
- Baltimore, Maryland Area 1991 - 1998
-
Faculty
Education:
The Johns Hopkins University School of Medicine 1983 - 1987
MD University of Pennsylvania 1978 - 1982
BA, Biology
MD University of Pennsylvania 1978 - 1982
BA, Biology
Methods To Identify Patients At Risk Of Developing Adverse Events During Treatment With Antidepressant Medication
US Patent:
7906283, Mar 15, 2011
Filed:
Oct 26, 2007
Appl. No.:
11/925334
Inventors:
Francis J. McMahon - Bethesda MD, US
Gonzalo E. Laje - Potomac MD, US
Silvia Paddock - Solna, SE
Husseini K. Manji - Cabin John MD, US
A. John Rush - Dallas TX, US
Gonzalo E. Laje - Potomac MD, US
Silvia Paddock - Solna, SE
Husseini K. Manji - Cabin John MD, US
A. John Rush - Dallas TX, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
Board of Regents, the University of Texas System - Austin IL
Board of Regents, the University of Texas System - Austin IL
International Classification:
C12Q 1/68, C12P 19/34, C07H 21/02, C07H 21/04
US Classification:
435 6, 435 912, 536 235, 536 2431
Abstract:
The invention provides a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising: (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); and combinations thereof.
Methods To Predict The Outcome Of Treatment With Antidepressant Medication
US Patent:
2008023, Sep 25, 2008
Filed:
Mar 19, 2008
Appl. No.:
12/051494
Inventors:
Francis J. McMahon - Bethesda MD, US
Gonzalo E. Laje - Potomac MD, US
Silvia Paddock - Solna, SE
Husseini K. Manji - Cabin John MD, US
Alexander F. Wilson - Phoenix MD, US
Gonzalo E. Laje - Potomac MD, US
Silvia Paddock - Solna, SE
Husseini K. Manji - Cabin John MD, US
Alexander F. Wilson - Phoenix MD, US
Assignee:
Gov. of the United States of America, represented by the Secretary, Dept. of Health and - Rockville MD
Board fo Regents, The University of Texas System - Austin TX
Board fo Regents, The University of Texas System - Austin TX
International Classification:
G01N 33/50
US Classification:
436 94
Abstract:
The invention provides a method for determining the outcome of treatment with an antidepressant medication in a patient. In particular, the invention provides a method of screening patients to identify those patients with a decreased risk of non-response to treatment with antidepressant medication comprising: (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with a decreased risk of non-response to treatment with antidepressant medication, wherein the genotype is characterized by a polymorphism in a HTR2A, GRIK4, BCL2, or a combination thereof.
Methods To Identify Patients At Risk Of Developing Adverse Events During Treatment With Antidepressant Medication
US Patent:
2011011, May 19, 2011
Filed:
Jan 27, 2011
Appl. No.:
13/015068
Inventors:
Francis J. McMahon - Bethesda MD, US
Gonzalo E. Laje - Potomac MD, US
Silvia Paddock - Solna, SE
Husseini K. Manji - Cabin John MD, US
A. John Rush - Dallas TX, US
Gonzalo E. Laje - Potomac MD, US
Silvia Paddock - Solna, SE
Husseini K. Manji - Cabin John MD, US
A. John Rush - Dallas TX, US
Assignee:
The United States of America, Represented by the Secretary, Department of Health - Bethesda MD
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
C40B 30/00
US Classification:
506 7
Abstract:
The invention provides a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising: (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); and combinations thereof.